Table 1.

Baseline characteristics and biopsy outcomes, JHH Prostate Cancer Active Surveillance cohort, 1994–2012

	Caucasian	African-American	p
N	615	39	-
Median age (years) (IQR)	65.6 (61.9, 68.8)	65.8 (62.1, 71.1)	0.346†
Median BMI (kg/m2) (IQR)	26.3 (24.4, 28.7)	27.1 (25.7, 30.4)	0.013†
Median PSA at diagnosis (ng/ml) (IQR)	4.4 (3.1, 5.6)	4.2 (2.2, 5.4)	0.255†
Median PSA density at diagnosis (ng/ml/cc) (IQR)	0.09 (0.06, 0.11)	0.07 (0.06, 0.09)	0.058†
Gleason at diagnosis ≤6	615 (100%)	39 (100%)	-
Positive cores at diagnosis			0.099
1	450 (75.9%)	25(64.1%)
2	143 (24.1%)	14 (35.9%)
Total cores sampled at first AS biopsy (mean, median, (IQR))	12.9, 12.0 (12.0, 12.0)	12.4, 12.0 (12.0, 12.5)	0.948†
Maximum percent cancer per core at diagnosis (median, IQR)	2.0 (1.0, 10.0)	5.0 (1.0, 10.0)	0.641†
Median PSA velocity (ng/ml/year) (IQR)	0.13 (−0.75, 1.15)	0.08 (−0.58, 1.45)	0.557†
Median PSA doubling time (months) (IQR)	100.0 (38.9, 100.0)	100.0 (48.6, 100.0)	0.409†
Location of first AS biopsy			<0.001
Johns Hopkins	100 (16.3%)	17 (43.6%)
Outside center	515 (83.7%)	22 (56.4%)
Reclassification on biopsy
Grade	99 (16.1%)	14 (35.9%)	<0.001‡
Volume	322 (52.4%)	19 (48.7%)	0.903‡
Either	366 (59.5%)	27 (69.2%)	0.019‡
Both	181 (29.4%)	15 (38.5%)	0.156‡
Reclassification to treatment	213 (34.6%)	17 (43.6%)	0.304§
Treatment subtypes			0.142
Radical prostatectomy	108/213 (50.9%)	5/17 (29.4%)
EBRT* +/− ADT**	93/213 (43.7%)	9/17 (52.9%)
Brachytherapy	9/213 (4.2%)	2/17 (11.8%)
Other	3/213 (1.4%)	1/17 (5.9%)
Median follow-up (months) IQR	36.3 (18.4, 61.3)	30.5 (16.4, 59.1)	0.536†

^†Wilcoxon-Mann-Whitney rank-sum p-value

^‡Competing risks regression p-value (unadjusted)

^§Log-rank p-value

^*External beam radiotherapy

^**Androgen deprivation therapy